Name | Stonerise Keyser |
---|---|
Location | 135 Southern Drive, Keyser, West Virginia |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 122 |
Occupancy Rate | 66.97% |
Medicare ID (CCN) | 515122 |
Legal Business Name | Keyser Center Llc |
Ownership Type | For Profit - Limited Liability Company |
NPI Number | 1861437253 |
Organization Name | HEARTLAND OF KEYSER WV LLC |
Doing Business As | HEARTLAND OF KEYSER |
Address | 135 Southern Dr, Keyser, WV 26726 |
Phone Number | 304-788-3415 |
News Archive
Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.
Recently published research from the University of Arizona Health Sciences shows that advanced-stage kidney cancer is more common in Hispanic Americans and Native Americans than in non-Hispanic whites, and that both Hispanic Americans and Native Americans in Arizona have an increased risk of mortality from the disease.
According to the Obama administration's 2014 budget document, the federal government will spend about $4 billion on federal- and state-run marketplaces for individual and small businesses purchasing insurance coverage.
Crospon has today announced that it has received FDA clearance for its EsoFLIP balloon dilation catheter. This is the first product the in what will be a suite of dilation catheter products to be used for dilation procedures in the esophagus and colon. It represents the company's first foray into the therapeutic endoscopy accessory market.
› Verified 1 days ago
NPI Number | 1902545288 |
Organization Name | SOUTHERN LEASING CO., LLC |
Doing Business As | STONERISE KEYSER |
Address | 135 Southern Dr, Keyser, WV 26726 |
Phone Number | 304-788-3415 |
News Archive
Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.
Recently published research from the University of Arizona Health Sciences shows that advanced-stage kidney cancer is more common in Hispanic Americans and Native Americans than in non-Hispanic whites, and that both Hispanic Americans and Native Americans in Arizona have an increased risk of mortality from the disease.
According to the Obama administration's 2014 budget document, the federal government will spend about $4 billion on federal- and state-run marketplaces for individual and small businesses purchasing insurance coverage.
Crospon has today announced that it has received FDA clearance for its EsoFLIP balloon dilation catheter. This is the first product the in what will be a suite of dilation catheter products to be used for dilation procedures in the esophagus and colon. It represents the company's first foray into the therapeutic endoscopy accessory market.
› Verified 1 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.
Recently published research from the University of Arizona Health Sciences shows that advanced-stage kidney cancer is more common in Hispanic Americans and Native Americans than in non-Hispanic whites, and that both Hispanic Americans and Native Americans in Arizona have an increased risk of mortality from the disease.
According to the Obama administration's 2014 budget document, the federal government will spend about $4 billion on federal- and state-run marketplaces for individual and small businesses purchasing insurance coverage.
Crospon has today announced that it has received FDA clearance for its EsoFLIP balloon dilation catheter. This is the first product the in what will be a suite of dilation catheter products to be used for dilation procedures in the esophagus and colon. It represents the company's first foray into the therapeutic endoscopy accessory market.
› Verified 1 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 18.01 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.3 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 53.85 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.16 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.55 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 6.61 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.47 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.2 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 18.53 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 76.88 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 8.16 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 33.67 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.33 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 15.28 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.92 | 95.98 |
Percentage of short-stay residents who made improvements in function | 46.09 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 72.77 | 82.93 |
News Archive
Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.
Recently published research from the University of Arizona Health Sciences shows that advanced-stage kidney cancer is more common in Hispanic Americans and Native Americans than in non-Hispanic whites, and that both Hispanic Americans and Native Americans in Arizona have an increased risk of mortality from the disease.
According to the Obama administration's 2014 budget document, the federal government will spend about $4 billion on federal- and state-run marketplaces for individual and small businesses purchasing insurance coverage.
Crospon has today announced that it has received FDA clearance for its EsoFLIP balloon dilation catheter. This is the first product the in what will be a suite of dilation catheter products to be used for dilation procedures in the esophagus and colon. It represents the company's first foray into the therapeutic endoscopy accessory market.
› Verified 1 days ago